Estefanía Prochetto

Recombinant Mycobacterium bovis BCG is a promising platform to develop vaccines against Trypansoma cruzi infection.

I. Marcipar, S. Borsuk, Gabriel Cabrera, 2020, Clinical and experimental immunology.

Genetic Engineering of Lactococcus lactis Co-producing Antigen and the Mucosal Adjuvant 3′ 5′- cyclic di Adenosine Monophosphate (c-di-AMP) as a Design Strategy to Develop a Mucosal Vaccine Prototype

I. Marcipar, J. Stülke, Gabriel Cabrera, 2018, Front. Microbiol..

Myeloid-derived suppressor cells and vaccination against pathogens

V. Sánchez-Margalet, Gabriel Cabrera, C. Jiménez-Cortegana, 2022, Frontiers in Cellular and Infection Microbiology.

Targeting Myeloid-Derived Suppressor Cells to Enhance a Trans-Sialidase-Based Vaccine Against Trypanosoma cruzi

I. Marcipar, Gabriel Cabrera, G. Lupi, 2021, Frontiers in Cellular and Infection Microbiology.

Trans-sialidase-based vaccine candidate protects against Trypanosoma cruzi infection, not only inducing an effector immune response but also affecting cells with regulatory/suppressor phenotype

I. Marcipar, Gabriel Cabrera, A. Pérez, 2017, Oncotarget.

Increased epicardial adipose tissue thickness associated with increased metabolic risk and the presence of heart failure in patients with Chronic Chagas disease.

I. Marcipar, Miguel Hernán Vicco, E. Prochetto, 2021, Transactions of the Royal Society of Tropical Medicine and Hygiene.